Boston Pharmaceuticals | Evaluate

No plain sailing for Novartis’s PD-1 plan

Getting the Swiss firm’s Beigene-derived anti-PD-1 MAb across the US finish line is proving harder than expected.

89bio’s home run fails to excite

The group gets a win in severe hypertriglyceridaemia, but a bigger readout in Nash awaits.

September 02, 2020

Novartis lets Boston take on Akero in Nash

July 14, 2020

Roche pits its targeted cancer Blueprint against Lilly

Roche must believe that Blueprint Medicines’ Ret inhibitor pralsetinib has a safety edge over Lilly’s Retevmo.